Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Cancer starts when cells in the body begin to grow out of control. Cells in nearly any part of the body can become cancer and can spread. To learn more about how cancers start and spread, see What Is Cancer?
Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but these tumors can also develop in other parts of the body, such as in the lymph nodes (bean-sized collections of immune cells throughout the body), the lungs, or digestive tract.
The abnormal cells of KS form purple, red, or brown blotches or tumors on the skin. These affected areas are called lesions. The skin lesions of KS most often show on the legs or face. They may look bad, but they usually cause no symptoms. Some lesions on the legs or in the groin area may cause the legs and feet to swell painfully.
KS can cause serious problems or even become life threatening when the lesions are in the lungs, liver, or digestive tract. KS in the digestive tract, for example, can cause bleeding, while tumors in the lungs may cause trouble breathing.
There are four different types of KS defined by the different populations it develops in, but the changes within the KS cells are very similar.
The most common type of KS in the United States is epidemic or AIDS-associated KS. This type of KS develops in people who are infected with HIV, the virus that causes AIDS.
HIV stands for human immunodeficiency virus. A person infected with HIV (someone who is HIV-positive) does not necessarily have AIDS, but the virus can be present in the body for a long time, often many years, before causing major illness. The disease known as AIDS begins when the virus has seriously damaged a person's immune system, which means they can get certain types of infections (such as Kaposi sarcoma--associated herpesvirus, KSHV) or other medical complications, including KS.
KS is considered an AIDS defining illness. This means that when KS occurs in someone infected with HIV, that person officially has AIDS (and is not just HIV-positive).
In the United States, treating HIV infection with highly active antiretroviral therapy (HAART) has resulted in fewer cases of AIDS-associated KS. Still, some patients can develop KS in the first few months of HAART treatment.
For most patients with HIV, HAART can often keep advanced KS from developing. Still, KS can occur in people whose HIV is well controlled with HAART. Even if KS develops, it is still important to continue HAART.
In areas of the world where it is not easy to get HAART, KS in AIDS patients can advance quickly.
Classic KS occurs mainly in older people of Mediterranean, Eastern European, and Middle Eastern heritage. Classic KS is more common in men than in women. People typically have one or more lesions on the legs, ankles, or the soles of their feet. Compared to other types of KS, the lesions in this type do not grow as quickly, and new lesions do not develop as often. The immune system of people with classic KS is not as weak as it is in those who have epidemic KS, but it may be weaker than normal. Getting older can naturally weaken the immune system a little. When this occurs, people who already have a KSHV (Kaposi sarcoma--associated herpesvirus) infection are more likely to develop KS.
Endemic KS occurs in people living in Equatorial Africa and is sometimes called African KS. Kaposi sarcoma--associated herpesvirus (KSHV) infection is much more common in Africa than in other parts of the world, so the risk of KS is higher. Other factors in Africa that weaken the immune system (such as malaria, other chronic infections, and malnutrition) also probably contribute to the development of KS, since the disease affects a broader group of people that includes children and women. Endemic KS tends to occur in younger people (usually under age 40). Rarely a more aggressive form of endemic KS is seen in children before puberty. This type usually affects lymph nodes and other organs and can progress quickly.
Endemic KS used to be the most common type of KS in Africa. Then, as AIDS became more common in Africa, the epidemic type became more common.
When KS develops in people whose immune systems have been suppressed after an organ transplant, it is called iatrogenic, or transplant-related KS. Most transplant patients need to take drugs to keep their immune system from rejecting (attacking) the new organ. But by weakening the body’s immune system, these drugs increase the chance that someone infected with KSHV (Kaposi sarcoma--associated herpesvirus) will develop KS. Stopping the immune-suppressing drugs or lowering their dose often makes KS lesions go away or get smaller.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
National Cancer Institute Physician Data Query (PDQ): Kaposi sarcoma treatment - Health Professional Version. 01/30/2018. Accessed at https://www.cancer.gov/types/soft-tissue-sarcoma/hp/kaposi-treatment-pdq accessed on March 12, 2018.
National Comprehensive Cancer Network (NCCN)—AIDS-Related Kaposi Sarcoma. V1.2018 (11/03/2017). Accessed 03/02/2018 from https://www.nccn.org/professionals/physician_gls/pdf/kaposi.pdf.
Noy A, Dickson M, Gulick RM, Palefsky J, Rubinstein PG, Steir E. Ch. 65 - Acquired Immunodeficiency Syndrome and Cancer. In: Niederhuber JE. Armitage JO, Kastan MB, Tepper JE. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, PA: Elsevier; 2014.
Radu O and Pantanowitz L. Kaposi Sarcoma. Arch Pathol Lab Med. 2013;137:289–294; doi: 10.5858/arpa.2012-0101-RS.
Yarchoan R, Uldrick TS, Polizzotto MN, Little RF. Ch. 117 - HIV-associated malignancies. In: DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2015.
Last Revised: April 19, 2018
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
If this was helpful, donate to help fund patient support services, research, and cancer content updates.